RP2 + Bevacizumab + Atezolizumab + Durvalumab + RP2 Monotherapy
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma, Biliary Tract Cancer
Trial Timeline
Aug 1, 2024 → Jul 1, 2028
NCT ID
NCT05733598About RP2 + Bevacizumab + Atezolizumab + Durvalumab + RP2 Monotherapy
RP2 + Bevacizumab + Atezolizumab + Durvalumab + RP2 Monotherapy is a phase 2 stage product being developed by Replimune for Hepatocellular Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05733598. Target conditions include Hepatocellular Carcinoma, Biliary Tract Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05733598 | Phase 2 | Recruiting |
Competing Products
20 competing products in Hepatocellular Carcinoma